Assembly Biosciences, Inc.

Indiana University

Cantero Therapeutics, Inc.

Hans Maag

Lee Daniel Arnold

William Wilson Turner, Jr

Mark G Bures

William W Turner

Leping Li

Simon Nicolas Haydar

Samson Francis

Adam Zlotnick

Yves Leblanc

Robert J Zamboni

Lynne Bannen

Miguel Xavier Fernandes

Elham Akbariromani

Pallavi Thakur

Marc-Andre Beaulieu

William Turner

Jr William W Turner

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Hepatitis b core protein modulators

The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

Triazole glycolate oxidase inhibitors

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula: 

Hepatitis B core protein modulators

Hepatitis B core protein allosteric modulators

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Hepatitis B viral assembly effectors

Growing community of inventors

Kleires Wiesental, Germany

Hans Maag